United States Patent 12,365,689 (Juvenile Idiopathic Arthritis) Scope, Claim Coverage, and US Patent Landscape
Executive summary: The US claims you provided for patent US 12,365,689 are directed to (i) a fixed-dose, once-daily tablet regimen for juvenile idiopathic arthritis (JIA) using a specific small-molecule “Compound 1” at 15 mg, and (ii) a broader, regimen-selection framework for polyarticular course JIA (pcJIA) using upadacitinib, with weight-banded pediatric dosing (solution BID at 3/4/6 mg) and an alternative 15 mg once-daily tablet option. Claim scope expands further through ACR/JIA ACR response endpoints at 12 and 48 weeks, JIA subtypes (RF+/- pcJIA, extended oligoarticular, and systemic JIA without active systemic features), and prior treatment constraints (inadequate response/intolerance to DMARDs including methotrexate and anti-TNF biologics). This profile makes the patent relevant as a method-of-treatment/instruction patent rather than a pure composition patent, and it heightens formulation/dosing and clinical endpoint design-around pressure for generics, biosimilar-adjacent competitors (where applicable), and label-copying efforts.
What patents protect juvenile idiopathic arthritis treatments like upadacitinib and the named “Compound 1” in the US?
Direct answer: US 12,365,689 claims protect specific dosing regimens for JIA, including (a) 15 mg once-daily tablets of “Compound 1” and (b) weight-banded pediatric upadacitinib regimens (solution BID or tablet QD) for pcJIA, plus outcome-tied subclaims using JIA ACR pediatric response at 12 and 48 weeks, and subtype/DMARD-exposure limitations.
What exactly is covered under Claim 1 (Compound 1, 15 mg QD tablet, once daily)?
- Population: “human patient … juvenile idiopathic arthritis”
- Regimen: “orally administering once daily… a tablet comprising … Compound 1”
- Dose: 15 mg therapeutically effective amount
- Frequency: once daily (QD)
Practical legal scope implications
- The claim is dose-specific (15 mg) and schedule-specific (once daily).
- It is route-specific (orally administering a tablet).
- It is agent-specific (Compound 1 with a defined chemical identity).
What exactly is covered under Claims 4-20 (upadacitinib pcJIA pediatric regimen selection)?
Claim 4 is a dosing algorithm with mutually exclusive branches:
- Weight 10 to <20 kg: upadacitinib oral solution 3 mg twice daily (3 mg BID)
- Weight 20 to <30 kg: upadacitinib oral solution 4 mg BID
- Weight ≥30 kg: either
- oral solution 6 mg BID, or
- tablet 15 mg once daily (15 mg QD)
Subclaims add:
- JIA subtypes: RF+ pcJIA, RF- pcJIA, extended oligoarticular JIA, systemic JIA “with active arthritis and without active systemic features” (Claims 9-12)
- Outcome endpoints at set times: JIA ACR pediatric 30/50/70/90 at 12 weeks after the first daily administration (Claims 13-16) and at 48 weeks (Claims 17-20)
- Prior therapy constraints: inadequate response or intolerance to DMARDs; DMARD specified as methotrexate or anti-TNF biologics (Claims 21-26)
- Age constraints: pediatric age 2 to <18 years (Claims 27-30)
Why the “endpoint” subclaims matter
Claims 13-20 tie infringement risk to achieving JIA ACR pediatric response thresholds at 12 and 48 weeks. Method-of-treatment patents that include endpoints can be enforced when:
- accused therapy is provided with the expectation of achieving those results, and
- the patient achieves those thresholds within the time window.
In practice, for litigation, these subclaims create a fact pattern that can be developed from trial charts, EHRs, registries, and post-marketing cohorts.
How broad are the claims of US 12,365,689 across JIA subtypes, doses, and patient characteristics?
Direct answer: Claim coverage spans (i) drug identity (Compound 1 and upadacitinib), (ii) dosage form (tablet vs oral solution), (iii) dose and schedule (15 mg QD for Compound 1; 3/4/6 mg BID solution bands and 15 mg QD tablet for upadacitinib), (iv) pediatric demographics (age 2 to <18), (v) prior DMARD exposure (including methotrexate and anti-TNF), (vi) disease subtype classification, and (vii) defined clinical response endpoints at 12 and 48 weeks.
Scope expansion matrix
| Claim cluster |
Covers |
Limits that narrow infringement |
| Claim 1 |
JIA treatment with Compound 1 tablet, 15 mg QD |
Tablet form, oral, once daily, exact 15 mg, oral administration |
| Claims 4-8 |
pcJIA pediatric upadacitinib regimen by weight band |
Solution vs tablet selection, 3/4/6 mg BID and 15 mg QD choices, weight thresholds |
| Claims 9-12 |
Specific pcJIA/systemic/extended oligoarticular categories |
Must fit the stated JIA subtype definitions |
| Claims 13-20 |
Achieving JIA ACR pediatric response at 12 and 48 weeks |
Patient must reach the specified response (30/50/70/90) at the timepoint |
| Claims 21-26 |
Prior DMARD inadequate response/intolerance |
Methotrexate and anti-TNF only where specified; otherwise “one or more DMARDs” |
| Claims 27-30 |
Pediatric age 2 to <18 + DMARD exposure types |
Age range and DMARD identity |
Key narrowing points that defendants typically target
- Dose exactness: 15 mg and 3/4/6 mg steps are sharp.
- Schedule: QD vs BID changes risk.
- Dosage form: oral solution vs tablet.
- Patient classification: JIA subtypes (RF+/- pcJIA; systemic JIA without active systemic features; extended oligoarticular).
- Outcome thresholds: JIA ACR pediatric 30/50/70/90 at defined weeks.
What parts of US 12,365,689 look like method-of-treatment claims vs composition claims?
Direct answer: All provided claims read as method-of-treatment/medical use claims with administration steps and (for some subclaims) clinical response endpoints. The “Compound 1” appears embedded as an agent definition in a regimen, not as an isolated composition claim.
Method-of-treatment characteristic features in this patent
- “comprising administering…”
- “therapeutically effective amount is 15 mg”
- “administering upadacitinib… wherein: if the pediatric patient has body weight… administer …”
- “wherein the pediatric patient achieves a JIA ACR pediatric 30/50/70/90 response at 12/48 weeks…”
Regimen-selection structure (Claim 4) is a litigation lever
If an accused regimen deviates from the weight-based algorithm or swaps solution/tablet or changes BID/QD, defendants can argue non-infringement because Claim 4’s branches are conditions with specific dosing.
When does US 12,365,689 lose exclusivity, and what does that imply for generic or biosimilar entry?
Direct answer: No expiration, PTA, pediatric exclusivity, or filing/publication dates were provided with the prompt. Under the operating constraints, a complete and accurate exclusivity timeline cannot be produced from the provided information alone, so no exclusivity dates are included here.
What Paragraph IV or generic entry risks exist for upadacitinib pediatric regimens under US 12,365,689?
Direct answer: The highest generic entry risk would be for label copying that mirrors the claimed pediatric weight-banded regimen (solution BID at 3/4/6 mg; tablet 15 mg QD for ≥30 kg) and for any asserted enforcement theory that alleges clinicians administered the regimen and patients achieved the JIA ACR pediatric thresholds at 12 or 48 weeks.
What entry scenarios are most likely to trigger infringement allegations
- A generic upadacitinib product launches and commercial marketing drives practice aligned with the claimed dosing algorithm.
- Real-world dosing in a post-launch cohort includes:
- the exact weight bands, and
- solution vs tablet usage as specified, and
- patients meeting JIA ACR pediatric endpoints at the timepoints.
Where design-arounds may exist (from the claim text alone)
- Changing to a dosing schedule that does not match the claim branches (QD vs BID).
- Using an alternative dosage form or strength that does not satisfy the “wherein” conditions.
- Treating subsets outside the constrained populations (e.g., not meeting age 2 to <18, not meeting DMARD inadequate response predicates, or not fitting the specified JIA subtype definitions where those subclaims are asserted).
What formulations are protected by US 12,365,689 (tablet vs oral solution) and how does this affect market competition?
Direct answer: Upadacitinib is claimed in two dosage-form contexts:
- Oral pharmaceutical solution for the 10 to <30 kg weight bands (3 mg BID and 4 mg BID) and optionally for ≥30 kg at 6 mg BID.
- Tablet 15 mg QD for ≥30 kg in one alternative branch.
Compound 1 is claimed as a tablet at 15 mg QD.
Formulation-centric infringement pressure
- Generics often compete on active ingredient, but method claims can attach to specific administration instructions and thus to labeling and prescribing practices.
- If a product’s label diverges from the claimed algorithm, infringement theories may shift toward off-label conduct.
How strong is the patent estate for JIA treatment claims like this: what other US patent types typically coexist?
Direct answer: With only the claims for US 12,365,689 provided, a reliable cross-patent mapping of the “estate” (continuations, divisionals, related compounds, polymorphs, process patents, dosing patents, and method-of-use patents) cannot be enumerated accurately. No additional patent numbers, family members, or assignee data were included in the prompt.
What litigation or FDA regulatory status affects US 12,365,689?
Direct answer: No FDA product listing, Orange Book entry, litigation docket, settlement, or regulatory pathway details were supplied. A litigation/regulatory landscape cannot be produced accurately without external record data.
Key Takeaways
- US 12,365,689 (per provided claims) is a method-of-treatment patent that locks onto:
- Compound 1: JIA tablet, 15 mg once daily (Claim 1).
- Upadacitinib: pcJIA pediatric dosing algorithm by weight band, using oral solution BID (3/4/6 mg) or 15 mg tablet QD for ≥30 kg (Claim 4).
- Coverage is expanded through:
- JIA subtype limitations (RF+/- pcJIA, extended oligoarticular JIA, systemic JIA without active systemic features),
- age range (2 to <18 years),
- prior DMARD inadequate response/intolerance including methotrexate and anti-TNF biologics, and
- clinical response endpoints (JIA ACR pediatric 30/50/70/90) at 12 and 48 weeks.
- The claim architecture creates clear non-infringement levers centered on dose, schedule, dosage form, weight band branch selection, and endpoint timing.
- A full US exclusivity timeline, Orange Book status, and family/estate mapping are not provided in the prompt and therefore are not included.
FAQs
-
Does Claim 4 require both oral solution and tablet options to be used, or is either branch sufficient?
The claim is drafted as alternatives within branches, so infringement turns on which branch’s conditions and regimen are administered.
-
If a pediatric patient hits a JIA ACR pediatric 50 at week 12 but not 30, is the response subclaim satisfied?
Separate subclaims exist for each threshold; proving the relevant threshold at the specified timepoint is the operative requirement.
-
Are the DMARD limitations mandatory for all embodiments of the patent?
No. They appear in specific dependent claims (21-26 and 28-30), so their applicability depends on which claims are asserted.
-
Is systemic JIA treatment covered even if the patient has active systemic features?
The systemic JIA subclaim limits coverage to “active arthritis and without active systemic features” (Claim 12).
-
Can substitution of a different upadacitinib dose strength avoid infringement?
Avoidance depends on whether the administered regimen still satisfies the claim’s specified dose, schedule, dosage form, and weight-band conditions.
References (APA)
No sources were cited because no external patent record, FDA records, Orange Book listings, or litigation documents were included in the prompt.
